The German BioNTech announced that the vaccine for Cocid-19 that it is developing together with Pfizer, will probably bring in 17 billion euros this year, as the (third) booster dose and the use of the vaccine in children are increasing.
Based on scheduled deliveries of up to 2.5 billion doses so far, BioNTech said in a statement that it expects revenue of 16-17 billion euros from the vaccine in 2021.
In August, its estimates spoke of 15.9 billion euros, based on orders plus a backlog of orders of about 2.2 billion installments at the time.
The data also includes significant payments from partners and the percentage of gross profits in the areas of its partners, the company added.
Pfizer, for its part, last week said it would raise $ 36 billion in 2021 from vaccine sales and forecasts another $ 29 billion in 2022, beating analysts’ estimates for both years.
BioNTech added that it is working on new versions of the vaccine that target the Delta and Alpha mutations, to create a “routine” of initiation and development, in case the need arises in the future for unknown – as yet – mutations in the virus.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
